Drug rebate agreement for granisetron

Summary

The tender concerns the conclusion of a non-exclusive rebate agreement for the active substance granisetron. DAK-Gesundheit intends to conclude framework agreements with as many interested pharmaceutical companies as possible for the medicines named by the bidder in Annex 2 to the contract. The agreement starts on 01/07/2026 and runs until 30/06/2028, with an option to extend it once by 12 months. The exact participation and compliance requirements must be checked in the tender documents.